OCN19-overexpressed human umbilical cord-derived mesenchymal stem cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for OCN19-overexpressed human umbilical cord-derived mesenchymal stem cells, covering 2024-12-17 to 2024-12-17. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus [Phase 2]